Targeting mitochondria: a new promising approach for the treatment of liver diseases

Area of Science:

• Hepatology
• Mitochondrial Biology
• Drug Delivery Systems

Background:

• Mitochondrial dysfunction is a key factor in various acute and chronic liver diseases.
• Mitochondrial uncoupling, characterized by decreased proton motive force and ATP depletion, significantly contributes to liver pathology.
• Dysfunctional mitochondria lead to lipid accumulation, oxidative stress, and hepatocyte death via necrosis or apoptosis.

Purpose of the Study:

• To review current strategies for drug delivery to mitochondria.
• To focus on mitochondria-targeted molecules for treating liver diseases.
• To explore novel selective molecules and nanocarrier technologies for addressing mitochondrial dysfunction in liver pathology.

Main Methods:

• Review of recent literature on mitochondrial drug delivery systems.
• Analysis of mitochondria-targeted molecules and their application in liver disease models.
• Evaluation of nanocarrier technology for targeted mitochondrial intervention.

Main Results:

• Mitochondrial dysfunction, including uncoupling, lipid dysregulation, and ROS overproduction, is central to liver disease pathogenesis.
• Targeting mitochondrial dysfunction presents a promising therapeutic strategy for liver diseases.
• Emerging approaches include selective molecules and nanocarriers for precise mitochondrial drug delivery.

Conclusions:

• Preventing mitochondrial alterations is a crucial therapeutic goal for liver diseases.
• Current therapies for liver diseases are limited by efficacy and side effects.
• Mitochondria-targeted drug delivery systems and novel molecules show potential for effective treatment of liver pathologies.